C-reactive protein and cardiovascular diseases

International Journal of Angiology

Volumn 12, Issue 1, 2003, Pages 1-12

  Prasad, Kailash ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHOLESTEROL; COMPLEMENT; CYTOKINE; FIBRINOGEN; HOMOCYSTEINE; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPROTEIN A; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ACUTE GRAFT REJECTION; ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BODY MASS; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; COMPLEMENT ACTIVATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; IMPLANTATION; INCIDENCE; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIVER CELL; MEASUREMENT; MONOCYTE; NEUTROPHIL; PERIPHERAL VASCULAR DISEASE; PHAGOCYTOSIS; PLASMA HALF LIFE; POSTOPERATIVE COMPLICATION; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SECRETION; PROTEIN SYNTHESIS; RECIPIENT; RESPIRATORY BURST; RESTENOSIS; REVIEW; SMOKING; STROKE; SYMPTOM; THROMBOCYTE AGGREGATION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0141455920     PISSN: 10611711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00547-003-1018-y     Document Type: Review

References (197)

1. Tillett WS, Francis T (1930) Serological reactions in pneumonia with non-protein somatic fraction of pneumococcus. J Exp Med 52:561-571.
2. Lofstrom G (1944) Comparison between the reactions of acute phase serum with pneumococcus C-polysaccharide and with pneumococcus type 27. Brit J Exp Pathol 25:21-26.
3. Hedlund P (1961) Clinical and experimental studies on C-reactive protein (acute phase protein). Acta Medica Scandinavica (suppl. 361) 169:1-71.
4. Kuller LH, Tracy RP, Shaten J, Meilahn EN (1996) Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144:537-547.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979.
6. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH (1997) Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 17:1121-1127.
7. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731-733.
8. Ridker PM, Glynn RJ, Hennekens CH (1998) C-reactive protein adds to the predictive value of total and HDL-cholesterol in determining risk of first myocardial infarction. Circulation 97:2007-2011.
9. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98:839-844.
10. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A (1999) Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99:855-860.
11. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J (2001) Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103:2531-2534.
12. Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165-2168.
13. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J (2000) C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20:2094-2099.
14. Abernethy TJ, Avery OT (1941) Occurrence during acute infections of protein not normally present in blood; distribution of reactive protein in patients' sera and effect of calcium on flocculation reaction with C-polysaccharide of pneumococcus. J Exp Med 73:173-182.
15. Osmand AP, Friedenson B, Gewurz H, Painter RH, Hofmann T, Shelton E (1977) Characterization of C-reactive protein and the complement subcomponent Clt as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci USA 74:739-743.
16. Woo P, Korenberg JR, Whitehead AS (1985) Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component. J Biol Chem 260:13384-13388.
17. Volanakis JE, Clements WL, Schrohenloher RE (1978) C-reactive protein: purification by affinity chromatography and physicochemical characterization. J Immunol Method 23:285-295.
18. Hurlimann J, Thorbecke G, Hochwald GM (1966) The liver as the site of C-reactive protein formation. J Exp Med 123:365-378.
19. Mackiewicz A, Speroff T, Ganapathi MK, Kushner I (1991) Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 146:3032-3037.
20. Baumann H, Richards C, Gauldie J (1987) Interaction among hepatocyte-stimulating factors, interleukin-1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (Hep G2) cells. J Immunol 139:4122-4128.
21. Campos SP, Wang Y, Koj A, Baumann H (1994) Insulin cooperates with IL-1 in regulating expression of alphal-acid glycoprotein gene in rat hepatoma cells. Cytokine 6:485-492.
22. Yue CC, Muller-Greven J, Dailey P, Lozanski G, Anderson V, Macintyre S (1996) Identification of a C-reactive protein binding site in two hepatic carboxylesterases capable of retaining C-reactive protein within the endoplasmic reticulum. J Biol Chem 271:22245-22250.
23. Yen-Watson B, Kushner I (1974) Rabbit CRP response to endotoxin administration: dose-response relationship and kinetics. Proc Soc Exp Biol Med 146:1132-1136.
24. Kushner I, Feldmann G (1978) Control of the acute phase response. Demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit. J Exp Med 148:466-477.
25. Claus DR, Osmand AP, Gewurz H (1976) Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med 87:120-128.
26. Yeh ET, Anderson HV, Pasceri V, Willerson JT (2001) C-reactive protein: linking inflammation to cardiovascular complications. Circulation 104:974-975.
27. Gotschlich EC, Edelman GM (1967) Binding properties and specificity of C-reactive protein. Proc Natl Acad Sci USA 57:706-712.
28. Siegel J, Osmand AP, Wilson MF, Gewurz H (1975) Interactions of C-reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations. J Exp Med 142:709-721.
29. McCarty M (1947) Occurrence during acute infections of protein not normally present in blood; crystallization of C-reactive protein. J Exp Med 85:491-498.
30. MacLeod CM, Avery OT (1941) The occurrence during acute infections of protein not normally present in the blood; isolation and properties of reactive protein. J Exp Med 73:183-190.
31. Rapport MM, Graf L (1956) Quantitative determination of C-reactive protein by complement fixation. Proc Soc Exp Biol Med 93:69-74.
32. Nilsson LA (1968) Qualitative analysis of acute phase protein antisera with the comparative interference diffusion-in-gel technique. Int Arch Allergy 33:16-28.
33. Singer JM, Pratz CM, Pader E, Elster SK (1957) The latex fixation test: agglutination test for the C-reactive protein and comparison with the capillary precipitin method. Am J Clin Pathol 28:614-618.
34. Kapyaho K, Welin MG, Tanner P, Karkkainen T, Weber T (1989) Rapid determination of C-reactive protein by enzyme immunoassay using two monoclonal antibodies. Scand J Clin Lab Invest 49:389-393.
35. Macy EM, Hayes TE, Tracy RP (1997) Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43:52-58.
36. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N (1998) Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 35:745-753.
37. Eda S, Kaufmann J, Molwitz M, Vorberg E (1999) A new method of measuring C-reactive protein, with a low limit of detection, suitable for risk assessment of coronary artery disease. Scand J Clin Lab Invest Suppl 230:32-35.
38. Borque L, Bellod L, Rus A, Seco ML, Galisteo-Gonzalez F (2000) Development and validation of an automated and ultrasensitive immunoturbidimetric assay for C-reactive protein. Clin Chem 46:1839-1842.
39. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N (2000) Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 46:461-468.
40. Rifai N, Ridker PM (2001) High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 47:403-411.
41. Rifai N, Tracy RP, Ridker PM (1999) Clinical efficacy of an automated high sensitivity C-reactive protein assay. Clin Chem 45:2136-2141.
42. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E (2001) Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47:444-450.
43. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM (2001) Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47:426-430.
44. Gabay C, Kushner I (1999) Acute phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454.
45. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type-2 diabetes mellitus. JAMA 286:327-334.
46. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Eng J Med 342:836-843.
47. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Eng J Med 331:417-424.
48. Biasucci LM, Liuzzo G, Colizzi C, Rizzello V (2001) Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. Ital Heart J 2:164-171.
49. Shah PK (2000) Circulating markers of inflammation for vascular risk prediction: are they ready for prime time. Circulation 101:1758-1759.
50. Fleck A, Myers MA (1985) Diagnostic and prognostic significance of the acute-phase proteins. In: The Acute-Phase Response to Injury and Infection. Gordon AH, Koj A, eds. Elsevier-Science Publishers B.V., Amsterdam, The Netherlands, pp 249-271.
51. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511.
52. Ridker PM (2001) High sensitivity C-reative protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813-1818.
53. Pepys MD, Baltz ML (1983) Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins and serum amyloid A protein). Adv Immunol. 34:141-212.
54. Anderson HC, McCarty M (1950) Determination of C-reactive protein in the blood as a measure of activity of disease process in acute rheumatic fever. Am J Med 8:445-455.
55. Claus DR, Osmand AP, Gewurz H (1976) Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med 87:120-128.
56. Gewurz H (1983) The biology of C-reactive protein In: The Biology of Immunologic Disease. Dixon FJ, Fisher DW, eds. Sinauer Associates Inc., Sunderland, Massachusetts, pp 139-153.
57. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB (1982) Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 47:239-243.
58. Pietila K, Harmoinen A, Hermens W, Simoons ML, Van de Werf F, Verstraete M (1993) Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur Heart J 14:915-919.
59. Berk BC, Weintraub WS, Alexander RW (1990) Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 65:168-172.
60. Becker GJ, Waldburger M, Hughes GR, Pepys MB (1980) Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 39:50-52.
61. Amos RS, Constable TJ, Crockson RA, Crockson AP, McConkey B (1977) Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Brit Med J 1:195-197.
62. Pepys MB (1981) C-reactive protein (CRP), serum amyloid P-component (SAP) and serum amyloid A protein (SAA) in autoimmune disease. In: Clinics in Immunology and Allergy. Holborow EJ, ed. W.B. Saunders Co. Ltd. Eastbourne. 1:77-101.
63. Cowling P, Ebringer R, Cawdell D, Ishii M, Ebringer A (1980) C-reactive protein, ESR, and klebsiella in ankylosing spondylitis. Ann Rheum Dis 39:45-49.
64. Parish WE (1976) Studies on vasculitis. VII. C-reactive protein as a substance perpetuating chronic vasculitis. Occurrence in lesions and concentrations in sera. Clin Allergy 6:543-550.
65. Lehner T, Adinolfi M (1980) Acute phase proteins, C9, factor B, and lysozome in recurrent oral ulceration and Behcet's Syndrome. J Clin Pathol 33:269-275.
66. Pepys MB (1982) Aspects of the acute phase response: C-reactive protein system. In: Clinical Aspects of Immunology. Lachmann PJ, Peters DK (eds). Blackwell Scientific Publication, Boston. 4th Ed. 1:50-71.
67. Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, Pepys MB (1997) Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 40:723-727.
68. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, Cohen AS (1984) Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 19:193-198.
69. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH (1997) Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 17:2167-2176.
70. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistence, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978.
71. Volanakis JE (2001) Human C-reactive protein: expression, structure and function. Mol Immunol 38:189-197.
72. Du Clos TW (2000) Function of C-reactive protein. Ann Med 32:274-278.
73. Schwalbe RA, Dahlbäck B, Coe JE, Nelsestuen GL (1992) Pentraxin family of proteins interact specifically with phosphorylcholine and/or phosphorylethanolamine. Biochemistry 31:4907-4915.
74. Salonen EM, Vartio T, Hedman K, Vaheri A (1984) Binding of fibronectin by the acute phase reactant C-reactive protein. J Biol Chem 259:1496-1501.
75. Du Clos TW, Zlock LT, Rubin RL (1988) Analysis of the binding of C-reactive protein to histones and chromatin. J Immunol 141:4266-4270.
76. Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE (2001) Topology and structure of Clq-binding site on C-reactive protein. J Immunol 166:3998-4004.
77. Kaplan MH, Volanakis JE (1974) Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with choline phosphatides, lecithin and sphingomyelin. J Immunol 112:2135-2147.
78. Mold C, Gewurz H, Du Clos TW (1999) Regulation of complement activation by C-reactive protein. Immunopharmacology 42:23-30.
79. Bhakdi S, Torzewski M, Klouche M, Hemmes M (1999) Complement and atherogenesis: binding of CRP to degraded, non-oxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 19:2348-2354.
80. Claus DR, Siegel J, Petras K, Skor D, Osmand AP, Gewurz H (1977) Complement activation by interaction of polyanions and polycations. III. Complement activation by interaction of multiple polyanions and polycations in the presence of C-reactive protein. J Immunol 118:83-87.
81. Mold C, Gewurz H (1980) Activation of the alternative pathway by liposomes: inhibitory effect of C-reactive protein. Fed Proc 39:702.
82. Pepys MB, Rowe IF, Baltz ML (1985) C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol 27:83-111.
83. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S (1999) Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 163:3957-3962.
84. Fiedel BA, Gewurz H (1976) Effects of C-reactive protein on platelet function. I. Inhibition of platelet aggregation and release reactions. J Immunol 116:1289-1294.
85. Hokama Y, Nagasawa LS, Uchida DA, Morita AH, Abad MA, Michimoto W (1978) Suppression of arachidonic acid and endoperoxide-analog stimulated platelet aggregation by sodium azide and protection of this effect by C-reactive protein. Fed Proc 37:1455.
86. Gewurz H, Zhang XH, Lint TF (1995) Structure and function of the pentraxins. Curr Opin Immunol 7:54-64.
87. Mortensen RF (1994) Macrophages and acute-phase proteins. In: Macrophage-pathogen Interactions. Zwilling BS, Eisenstein TK (eds). Marcel Dekker, New York, NY pp 143-158.
88. Potempa LA, Zeller JM, Fiedel BA, Kinoshita CM, Gewurz H (1988) Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation 12:391-405.
89. Gessler P, Nebe T, Birle A, Haas N, Kachel W (1996) Neutrophil respiratory burst in term and preterm neonates without signs of infection and in those with increased levels of C-reactive protein. Pediatr Res 39:843-848.
90. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW (1999) The major receptor for C-reactive protein on leukocytes is Fcy receptor II. J Exp Med 190:585-590.
91. Kindmark CO (1971) Stimulating effect of C-reactive protein on phagocytosis of various species of pathogenic bacteria. Clin Exp Immunol 8:941-948.
92. Tellado JM, Christou NV (1993) Circulating and exudative polymorphonuclear neutrophil priming and oxidative capacity in anergic surgical patients. Arch Surg 128:691-695.
93. Buchta R, Fridkin M, Pontet M, Contessi E, Scaggiante B, Romeo D (1987) Modulation of human neutrophil function by C-reactive protein. Eur J Biochem 163:141-146.
94. Edwards KM, Gewurz H, Lint FT, Mold C (1982) A role for C-reactive protein in the complement-mediated stimulation of human neutrophils by type 27 Streptococcus pneumoniae. J Immunol 128:2493-2496.
95. Mortensen RF, Osmand AP, Lint TF, Gewurz H (1976) Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis. J Immunol 117:774-781.
96. Shephard EG, Anderson R, Strachan AF, Kuhn SH, DeBeer FC (1986) CRP and neutrophils: functional effects and complex uptake. Clin Exp Immunol 63:718-727.
97. Zeller JM, Landay AL, Lint TF, Gewurz H (1986) Enhancement of human peripheral blood monocyte respiratory burst activity by aggregated C-reactive protein. J Leukoc Biol 40:769-783.
98. Zeller JM, Landay AL, Lint TF, Gewurz H (1986) Aggregated C-reactive protein binds to human polymorphonuclear leukocytes and potentiates Fc receptor-mediated chemiluminescence. J Lab Clin Med 108:567-576.
99. Zeller JM, Sullivan BL (1992) C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by IgG-stimulated monocytes and neutrophils. J Leukoc Biol 52:449-455.
100. Prasad K (2003) Increased oxygen radical generation by neutrophils with C-reactive protein. Submitted.
101. Yasunari K, Maeda K, Nakamura M, Yoshikawa J (2002) Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose and C-reacting protein. Hypertension 39:777-780.
102. Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165-2168.
103. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE (1999) C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 100:96-102.
104. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J (2001) Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103:2531-2534.
105. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM (1993) C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82:513-520.
106. Ballou SP, Lozanski G (1992) Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 4:361-368.
107. Verhamme P, Quarck R, Hao H, Knaapen M, Dymarkowski S, Berner H, Van Cleemput J, Janssens S, Vermylen J, Gabbiani G, Kockx M, Holvoet P (2002) Dietary cholesterol withdrawal reduces vascular inflammation and induces coronary plaque stabilization in miniature pigs. Cardiovasc Res 56:135-144.
108. Chi DS, Jin FX, Yang SG, Su YW, Ge B, Zhang J, Zhang Y, Liu YL (2002) Effects of fluvastatin on the levels of C-reactive protein and lipids in patients with hyperlipidemia. Di Yi Jun Yi Da Xue Xue Bao 22:1109-1111.
109. Ridker PM, Rifai N, Lowenthal SP (2001) Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103:1191-1193.
110. Ridker PM, Glynn RJ, Hennekens CH (1998) C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97:2007-2011.
111. Lee IT, Sheu WH, Lin SY, Lee WJ, Song YM, Liu HC (2002) Simvastatin reduces plasma concentration of high sensitivity C-reactive protein in type-2 diabetic patients with hyperlipidemia. J Diabetes Complications 16:382-385.
112. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, DeVoe MC, Fakiolas N, Pissimissis EG, Olympios CD, Foussas SG (2002) The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting. The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 40:1375-1382.
113. Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481-2485.
114. Gotto AM Jr. (2002) Statins and C-reactive protein: considering a novel marker of cardiovascular risk. Prev Cardiol 5:200-203.
115. Moon YS, Kashyap ML (2002) Niacin extended-release/lovastatin: combination therapy for lipid disorders. Expert Opin Pharmacother 3:1763-1771.
116. Bismuth J, Kofoed SC, Jensen AS, Sethi A, Sillesen H (2002) Serum lipids act as inverse acute phase reactants and are falsely low in patients with critical limb ischemia. J Vasc Surg 36:1005-1010.
117. Webster RO, Hong SR, Johnston RB Jr, Henson PM (1980) Biological effects of the human complement fragments C5a and C5a des Arg on neutrophil function. Immunopharmacology 2:201-219.
118. Rouis M, Nigon F, Chapman MJ (1998) Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophages. Biochem Biophys Res Commun 156:1293-1301.
119. Stewart AG, Dubbin PN, Harris T, Dusting GJ (1990) Platelet-activating factor may act as a second messenger in the release of icosanoids and superoxide anions from leukocytes and endothelial cells. Proc Natl Acad Sci USA 87:3215-3219.
120. Braquet P, Hosford D, Braquet M, Bourgain R, Bussolino F (1989) Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol 88:88-100.
121. Prasad K, Kalra J (1993) Oxygen radicals and hypercholesterolemic atherosclerosis: Effect of Vitamin E. Am Heart J 125:958-973.
122. Prasad K, Kalra J, Lee P (1994) Oxygen radicals as a mechanism of hypercholesterolemic atherosclerosis: Effects of probucol. Int J Angiol 3:100-112.
123. Steinberg D (1992) Antioxidants in the prevention of human atherosclerosis. Circulation 85:2337-2344.
124. Prasad K (1999) Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 99:1355-1362.
125. Schwartz CJ, Valente AJ, Sprague EA (1988) A modern view of atherogenesis. Am J Cardiol 71(suppl B): B9-B14.
126. Steinberg D (1991) Antioxidants and atherosclerosis. A current assessment. Circulation 84:1420-1425.
127. Gimbrone MA Jr. (1995) Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol 75:67B-70B.
128. Cybulsky MI, Iiyma K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS (2001) A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107:1255-1262.
129. Holvoet P, Collen D (1997) Thrombosis and atherosclerosis. Curr Opin Lipidol 8:320-328.
130. Gearing AJ, Newman W (1993) Circulating adhesion molecules in disease. Immunol Today 14:506-512.
131. Chiu JJ, Wung BS, Shyy JY, Hsieh HJ, Wang DL (1997) Reactive oxygen species are involved in shear-stress induced intercellular adhesion molecule-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 17:3570-3577.
132. Martin A, Foxall T, Blumberg JB, Meydani M (1997) Vitamin E inhibits low-density lipoprotein-induced adhesion of monocytes to human aortic endothelial cells in vitro. Arterioscler Thromb Vasc Biol 17:429-436.
133. Polack B, Pernod G, Barro C, Doussiere J (1997) Role of oxygen radicals in tissue factor induction by endotoxin in blood monocytes. Haemostasis 27:193-200.
134. Shatos MA, Doherty JM, Orfeo T, Hoak JC, Collen D, Stump DC (1992) Modulation of the fibrinolytic response of cultured human vascular endothelium by extracellularly generated oxygen radicals. J Biol Chem 267:597-601.
135. Cianflone D, Ciccirillo F, Buffon A, Trani C, Scabbia EV, Finocchiaro ML, Crea F (1995) Comparison of coronary angiographic narrowing in stable angina pectoris, unstable angina pectoris, and in acute myocardial infarction. Am J Cardiol 76:215-219.
136. Berk BC, Weintraub WS, Alexander RW (1990) Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 65:168-172.
137. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ. Serradimigni A, Collen D (1989) Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 9:362-367.
138. Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore JR, Caligiuri G, Lanza GA, Quaranta G, Monaco C, Pepys MB, Maseri A (1996) Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 94:2373-2380.
139. Rebuzzi AG, Quaranta G, Liuzzo G, Caligiuri G, Lanza GA, Gallimore JR, Grillo RL, Cianflone D, Biasucci LM, Maseri A (1998) Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 82:715-719.
140. Heeschen C, Hamm CW, Bruemmer J, Simoons ML (2000) Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 35:1535-1542.
141. Rifai N, Ridker PM (2001) Proposed cardiovascular risk assessment algorithm using high sensitivity C-reactive protein and lipid screening. Clin Chem 47:28-30.
142. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237-242.
143. Braunwald E, Shattuck Lecture (1997) Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337:1360-1369.
144. Pepys MB, Hirschfield GM (2001) C-reactive protein and atherothrombosis. Ital Heart J 2:196-199.
145. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E (1998) C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI IIA Substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 31:1460-1465.
146. Das I (1985) Raised C-reactive protein levels in serum from smokers. Clin Chim Acta 153:9-13.
147. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1998) Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97:425-428.
148. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, Kropf J, Kerber S, Breithardt G, Assmann G, Cullen P (1999) Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol, 19:2355-2363.
149. Van der Meer IM, De Maat MP, Bots ML, Breteler MM, Meijer J, Kiliaan AJ, Hofman A, Witteman JC (2002) Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 22:838-842.
150. Folsom AR, Pankow JS, Tracy RP, Arnett DK, Peacock JM, Hong Y, Djousse L, Eckfeldt JH (2001) Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 88:112-117.
151. Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, Iyama S, Yamanishi H, Matsumoto M, Hori M (2001) C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 104: 63-67.
152. Van der Meer IM, De Maat MP, Hak AE, Kiliaan AJ, De Sol AI, Van der Kuip DA, Nijhuis RL, Hofman A, Witteman JC (2002) C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke 33:2750-2755.
153. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A (1999) Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 34:1512-1521.
154. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM (2001) Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 37:839-846.
155. Chew DP, Bhatt DL, Robbins MA (2001) Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 104:992-997.
156. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, DeVoe MC, Fakiolas CN, Pissimissis EG, Olympios CD, Foussas SG (2002) The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting. The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 40:1375-1382.
157. Zhou YF, Csako G, Grayston JT, Wang SP, Yu ZX, Shou M, Leon M, Epstein SE (1999) Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol 84:595-598.
158. Adar R, Critchfield GC, Eddy DM (1989) A confidence profile analysis of the results of femoropopliteal percutaneous transluminal angioplasty in the treatment of lower-extremity ischemia. J Vasc Surg 10:57-67.
159. Jeans WD, Armstrong S, Cole SE, Horrocks M, Baird RN (1990) Fate of patients undergoing transluminal angioplasty for lower-limb ischemia. Radiology 177:559-564.
160. Tschöpl M, Tsakiris DA, Marbet GA, Labs KH, Jäger K (1997) Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol 17:3208-3214.
161. Schillinger M, Haumer M, Schlerka G, Miekusch W, Exner M, Ahmadi R, Minar E (2001) Restenosis after percutaneous transluminal angioplasty in patients with peripheral arterial disease: the role of inflammation. J Endovasc Ther 8:477-483.
162. Schillinger M, Exner M, Mlekusch W, Rumpold H, Ahmadi R, Sabeti S, Haumer M, Wagner O, Minar E (2002) Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. Radiology 225:21-26.
163. Fadl YY, Zareba W, Moss AJ, Marder VJ, Sparks CS, Miller Watelet LF, Carroll ER (2003) History of hypertension and enhanced thrombogenic activity in postinfarction patients. Hypertension 41:943-949.
164. Rohde LE, Hennekens CH, Ridker PM (1999) Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 84:1018-1022.
165. Chae CU, Lee RT, Rifai N, Ridker PM (2001) Blood pressure and inflammation in apparently healthy men. Hypertension 38:399-403.
166. Li YN, Yuan H, Zhang MX (2001) Study on endothelial dysfunction and platelet activation in elderly hypertensive patients complicated with cerebral infarction. Human Yi Ke Da Xue Xue Bao 26:143-145.
167. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH (1997) Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 17:2167-2176.
168. Engström G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgärde F (2002) Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke 33:2744-2749.
169. Bach F, Grundmann U, Bauer M, Buchinger H, Soltesz S, Graeter T, Larsen R, Silomon M (2002) Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia. Acta Anaesthesiol Scand 46:1227-1235.
170. Berendes E, Mollhoff T, Van Aken H, Erren M, Deng MC, Loick HM (1997) Increased plasma concentrations of serum amyloid A: an indicator of the acute-phase response after cardiopulmonary bypass. Crit Care Med 25:1527-1533.
171. Mair P, Hoermann C, Mair J, Margreiter J, Puschendorf B, Balogh D (1999) Effects of a leukocyte depleting arterial line filter on perioperative proteolytic enzyme and oxygen free radical release in patients undergoing aortocoronary bypass surgery. Acta Anaesthesiol Scand 43:452-457.
172. Sgoutas DS, Lattouf OM, Finlayson DC, Clark RV (1992) Paradoxical response of plasma lipoprotein (a) in patients undergoing cardiopulmonary bypass. Atherosclerosis 97:29-36.
173. Boeken U, Feindt P, Zimmerman N, Kalweit G, Petzold T, Emmeran G (1998) Increased preoperative C-reactive protein values without signs of an infection and complicated course after cardiopulmonary bypass operations. Eur J Cardiothorac Surg 13:541-545.
174. Gaudino M, Nasso G, Andreotti F, Minniti G, Iacoviello L, Donati M, Schiavello R, Possati G (2002) Preoperative C-reactive protein level and outcome following coronary surgery. Eur J Cardiothorac Surg 22:521-526.
175. Mollhoff T, Loick HM, Van Aken H, Schmidt C, Rolf N, Tijan TD, Asfour B, Berendes E (1999) Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). Anesthesiology 90:72-80.
176. Sandler S, Bendtzen K, Eizirik DL, Welsh M (1990) Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 126:1288-1294.
177. Ford ES (1999) Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care 22:1971-1977.
178. Festa A, D'Agostino R Jr., Howard G, Mykkanen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42-47.
179. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W (2000) Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 23:1835-1839.
180. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio A, Tracy RP, Furberg CD, Psaty BM (2003) Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107:87-92.
181. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Giovannini L, Norpoth M, Metelli MR, Cristofani R, Bertelli AA, Sbragia G, Tetta C, Palla R, Colombo R (2002) C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 91:594-600.
182. Ortega O, Rodrigues I, Gallar P, Carreno A, Ortiz M, Espejo B, Jimenez J, Gutierrez M, Oliet A, Vigil A (2002) Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant 17:1105-1109.
183. Park CW, Shin YS, Kim CM, Lee SY, Yu SE, Kirn SY, Choi EJ, Chang YS, Bang BK (2002) Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in cardiac hemodialysis patients. Am J Kidney Dis 40:1230-1239.
184. Rahmati MA, Craig RG, Homel P, Kaysen GA, Levin NW (2002) Serum markers of periodontal disease status and inflammation in hemodialysis patients. Am J Kidney Dis 40:983-989.
185. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM (2002) C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 62:1417-1422.
186. Van Tellingen A, Grooteman MP, Schoorl M, Bartels PC, Schoorl M, Van der Ploeg T, ter Wee PM, Nube MJ (2002) Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int 62:632-638.
187. Koulouridis E, Tzilianos M, Katsarou A, Costimba I, Klonou E, Panagiotaki E, Georgalidis C, Krokida A, Delaportas N, Lachanas A, Karaliotas G, Kaliolia I (2001) Homocysteine and C-reactive protein levels in haemodialysis patients. Int Urol Nephrol 33:207-215.
188. Preston GA, Barrett CV, Alcorta DA, Hogan SL, Dinwiddie L, Jennette JC, Falk RJ (2002) Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron 92:817-823.
189. Iseki K, Tozawa M, Yoshi S, Fukiyama K (1999) Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 14:1956-1960.
190. Yeun JY, Levine RA, Mantadilok V, Kaysen GA (2000) C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35:469-476.
191. Haubitz M, Brunkhorst R, Wrenger E, Froese P, Schulze M, Koch KM (1996) Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Perit Dial Int 16:158-162.
192. Haubitz M, Schulze M, Koch KM (1990) Increase of C-reactive protein serum values following haemodialysis. Nephrol Dial Transplant 5:500-503.
193. Perez RV, Brown DJ, Katznelson SA, Dubin JA, Muller HG, Chang T, Rudich SM, McVicar JP, Kaysen GA (2000) Pretransplant systemic inflammation and acute rejection after renal transplantation. Transplantation 69:869-874.
194. Fink JC, Onuigbo MA, Blahut SA, Christenson RH, Mann D, Bartlett ST, Weir MR (2002) Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. Am J Kidney Dis 39:1096-1101.
195. Prasad K, Kalra J, Chan WP, Chaudhary AK (1989) Effect of oxygen free radicals on cardiovascular function at organ and cellular levels. Am Heart J 117:1196-1202.
196. Prasad K, Kalra J, Chaudhary AK, Debnath D (1990) Effect of polymorphonuclear leukocyte-derived oxygen free radicals and hypochlorous acid on cardiac function and some biochemical parameters. Am Heart J 119:538-550.
197. Prasad K, Kalra J, Bharadwaj B (1993) Cardiac depressant effects of oxygen free radicals. Angiol 44:257-270.